Masafumi Ono

Prof. Dr. Masafumi Ono


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Hepatology Research
Verified
Journal Article
Closed access
HFHideki Fujii
Hideki Fujii
YSYuichiro Suzuki
Yuichiro Suzuki
KSKoji Sawada
Koji Sawada
MTMiwa Tatsuta
Miwa Tatsuta
TMTatsuji Maeshiro
Tatsuji Maeshiro
J(Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD)
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG‐NAFLD)

22 April 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Hirokazu TakahashiHirokazu Takahashi
Hirokazu Takahashi
MKMiwa Kawanaka
Miwa Kawanaka
HFHideki Fujii
Hideki Fujii
MIMichihiro Iwaki
Michihiro Iwaki
HHHideki Hayashi
Hideki Hayashi
J(Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)
The relationship between baseline serum albumin level and long-term prognosis of patients with nonalcoholic fatty liver disease (NAFLD) remains unknown. This is a sub-analysis of the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) study. The main outcomes were: death or orthotopic liver transplantation (OLT), liver-related death, and liver-related events (hepatocellular carcinoma [HCC], decompensated cirrhosis, and gastroesophageal varices/bleeding). 1383 Japanese patients with biopsy-confirmed NAFLD were analyzed. They were divided into 3 groups based on serum albumin: high (>4.0 g/dL), intermediate (3.5–4.0 g/dL), and low (<3.5 g/dL). Unadjusted hazard ratio [HR] of the intermediate albumin group, compared with the high albumin group, were 3.6 for death or OLT, 11.2 for liver-related death, 4.6 for HCC, 8.2 for decompensated cirrhosis, and 6.2 for gastroesophageal varices (all risks were statistically significant). After adjusting confounding factors, albumin remained significantly associated with death or OLT (intermediate vs. high albumin group: HR 3.06, 95% confidence interval [CI] 1.59–5.91, p < 0.001; low vs. high albumin group: HR 22.9, 95% CI 8.21–63.9, p < 0.001). Among biopsy-confirmed NAFLD patients, those with intermediate or low serum albumin had a significantly higher risk of death or OLT than those with high serum albumin.

23 June 2023 in Hepatology Research
Verified
Journal Article
Closed access
TNTakako Nomura
Takako Nomura
MOMasafumi Ono
Masafumi Ono
KKKiyoyuki Kobayashi
Kiyoyuki Kobayashi
YAYuzuru Akaiwa
Yuzuru Akaiwa
MAMaki Ayaki
Maki Ayaki
TMTsutomu Masaki
Tsutomu Masaki

23 December 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
Yoshihiro KamadaYoshihiro Kamada
Yoshihiro Kamada
KMKensuke Munekage
Kensuke Munekage
TNTakashi Nakahara
Takashi Nakahara
HFHideki Fujii
Hideki Fujii
YSYoshiyuki Sawai
Yoshiyuki Sawai
MOMasafumi Ono
Masafumi Ono
The prognosis of nonalcoholic fatty liver disease (NAFLD) patients depends on liver-related events (LREs), extrahepatic cancers, and major adverse cardiovascular events (MACEs). The fibrosis-4 (FIB-4) index is one of the most reliable and useful predictors of the degree of liver fibrosis. Recent studies have reported that the FIB-4 index is also useful for predicting LREs and MACEs in NAFLD patients. In the present study, we investigated the prognostic value of the FIB-4 index in NAFLD patients. A total of 506 biopsy-confirmed NAFLD patients from six hepatology centers in Japan from 2002 to 2013 were enrolled in this study. Of these NAFLD patients, 353 were available for more than 100 days of follow-up and did not exhibit events (LREs, extrahepatic cancers, MACEs) at the time of entry. The mean follow-up duration of all the subjects was 2716 ± 1621 days (102–7483 days). New LREs (hepatocellular carcinoma (HCC) (n = 8), decompensation (n = 11), bleeding varices (n = 8)) developed in 18 patients. Twenty-four and twelve patients developed extrahepatic cancers and MACEs, respectively. The median FIB-4 index was 1.255; we divided our cohort into two groups according to this (FIB4 Low, FIB4 Hi). The incidence of HCC tended to be higher in FIB4 Hi (n = 7) than in FIB4 Low (n = 1). The incidence of LREs was significantly higher in FIB4 Hi (n = 17) than in FIB4 Low (n = 1). The incidence of extrahepatic cancers was significantly higher in FIB4 Hi (n = 20) than in FIB4 Low (n = 4); the incidence of MACEs was also significantly higher in FIB4 Hi (n = 10) than in FIB4 Low (n = 2). The FIB-4 index is a useful biomarker for predicting not only LREs but also extrahepatic cancers and MACEs.

23 December 2021 in Digestive Diseases
Verified
Journal Article
Open access
PDF file
LKLeslie Y. Kam
Leslie Y. Kam
DHDaniel Huang
Daniel Huang
MTMargaret L.P. Teng
Margaret L.P. Teng
Hirokazu TakahashiHirokazu Takahashi
Hirokazu Takahashi
KTKenichi Tanaka
Kenichi Tanaka
Mindie H. NguyenMindie H. Nguyen
Mindie H. Nguyen
Introduction: NAFLD is increasingly prevalent in Asia, where people suffer more metabolic comorbidities at a lower body mass index (BMI), suggesting potential differences in their clinical profile. Therefore, we attempted to characterize the clinical profile of Asians with NAFLD via a meta-analytic approach. Methods: We searched PubMed, EMBASE, and Cochrane databases from January 1, 2000, to January 17, 2019. Two authors independently reviewed and selected 104 articles (2,247,754 persons) that identified NAFLD in Asians and reported relevant data, especially BMI and ALT, and excluded individuals with other liver disease and excessive alcohol consumption. Individual patient-level data were obtained from seven cohorts in Asia to complement meta-analyzed data. Results: Overall, the mean age was 52.07 (95% CI: 51.28–52.85) years, with those from Southeast Asia (42.66, 95% CI: 32.23–53.11) being significantly younger. The mean BMI was 26.2 kg/m2, higher in moderate-severe versus mild hepatic steatosis (28.3 vs. 25.7) patients and NFS ≥ −1.455 versus <−1.455 (27.09 vs. 26.02), with 34% having nonobese NAFLD. The mean ALT was 31.74 U/L, higher in NFS < −1.455 versus ≥−1.455 (33.74 vs. 27.83), though no differences were found by obesity or steatosis severity. The majority of males (85.7%) and females (60.7%) had normal to minimally elevated ALT (1–1.5 × 95% ULN). Individual patient-level data analysis (N = 7,668) demonstrated similar results. Conclusion: About one-third of Asians with NAFLD were nonobese, and the majority did not have markedly elevated ALT. Therefore, abnormal ALT or BMI is not recommended as a criterion for NAFLD screening in this population. Additionally, there were significant differences in the clinical profiles of NAFLD among the different regions of Asia.

Verified
Journal Article
Open access
PDF file
AMAsahiro Morishita
Asahiro Morishita
KOKyoko Oura
Kyoko Oura
TTTomoko Tadokoro
Tomoko Tadokoro
KFKoji Fujita
Koji Fujita
JTJoji Tani
Joji Tani
TMTsutomu Masaki
Tsutomu Masaki
Non-alcoholic fatty liver disease (NAFLD) is a clinicopathologic syndrome caused by fat deposition in hepatocytes. Patients with nonalcoholic steatohepatitis (NASH), an advanced form of NAFLD with severe fibrosis, are at high risk for liver-related complications, including hepatocellular carcinoma (HCC). However, the mechanism of progression from simple fat deposition to NASH is complex, and previous reports have linked NAFLD to gut microbiota, bile acids, immunity, adipokines, oxidative stress, and genetic or epigenetic factors. NASH-related liver injury involves multiple cell types, and intercellular signaling is thought to be mediated by extracellular vesicles. MicroRNAs (miRNAs) are short, noncoding RNAs that play important roles as post-transcriptional regulators of gene expression and have been implicated in the pathogenesis of various diseases. Recently, many reports have implicated microRNAs in the pathogenesis of NALFD/NASH, suggesting that exosomal miRNAs are potential non-invasive and sensitive biomarkers and that the microRNAs involved in the mechanism of the progression of NASH may be potential therapeutic target molecules. We are interested in which miRNAs are involved in the pathogenesis of NASH and which are potential target molecules for therapy. We summarize targeted miRNAs associated with the etiology and progression of NASH and discuss each miRNA in terms of its pathophysiology, potential therapeutic applications, and efficacy as a NASH biomarker.